MD Anderson received FDA IND clearance to start a phase I trial of JV-394, a CAR T-cell therapy targeting CD94-positive T and natural killer lymphomas. The study will enroll patients with relapsed or refractory disease, creating a new regulatory pathway for an immunotherapy aimed at a relatively specific cell-surface marker. The clearance highlights continued investment in next-wave CAR T targets beyond classic CD19 and BCMA approaches, with the trial design positioned to generate early safety and activity data in a rare hematologic subset.